Bafna Pharma 31st AGM: All 3 resolutions passed with near-unanimous support

Board & Shareholder Meetings View source PDF Explain this filing

BAFNAPH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+2.3%1-day move

₹301.45

prior close

—

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

————+2.3+2.8+5.2+7.3+9.5+13.8+33.3———

Up moveDown movePending

AI summary

Bafna Pharmaceuticals held its 31st AGM on September 11, 2026 via video conferencing. All 3 ordinary resolutions passed with 99.9999% in favor. Total votes polled were about 1.81 crore shares (76.76% of outstanding). Resolutions covered: adoption of FY26 audited financials, re-appointment of Mr. Upendar Mekala Reddy as director, and ratification of cost auditor remuneration for FY27.

Likely market impact

Routine AGM. All resolutions passed overwhelmingly with strong promoter backing, signaling stable governance. No material change expected.